Abstract
Atypical hemolytic uremic syndrome (aHUS) although rare is the commonest cause of acute renal failure (ARF) in children and has poor prognosis. We present single centre experience of aHUS. Thirty six children (29 males, 7 females) with mean age, 7.9 years presented with ARF, 2 children also had tonic–clonic type convulsions. Their hematology examination revealed hemolytic anemia with s. creatinine (SCr), 5.54 mg/dl. Acute HUS was observed in 75 %, acute on chronic HUS in 19.4 % and patchy cortical necrosis (PCN) in 5.6 % biopsies. Mean 5.4 plasma exchanges (PE) were carried out. Supportive management of anti-hypertensives and prednisone was also given. Recovery end points were establishment of urine output, improvement of SCr and hematological profile. Hematology and renal function profile improved variably in all children, 5.6 % died, relapse was observed in 80.5 % over mean 70 days; 13.9 % children are doing well over mean follow-up of 268.8 days. Thus poor prognosis was observed in 86.1 % children. Children with acute on chronic HUS and PCN did not recover. Six children who recovered had acute HUS. aHUS in Indian children occurs at an older age of around 8 years and chronic/irreversible changes on histopathology examination are harbingers of poor prognosis. PE is life-saving however further research for developing strategies to improve long-term survival is needed.
Similar content being viewed by others
Abbreviations
- ARF:
-
Acute renal failure
- aHUS:
-
Atypical hemolytic uremic syndrome
- CAPD:
-
Continuous ambulatory peritoneal dialysis
- CBC:
-
Complete blood counts
- CRF:
-
Chronic renal failure
- FFP:
-
Fresh frozen plasma
- Hb:
-
Hemoglobin
- HUS:
-
Hemolytic uremic syndrome
- IF:
-
Immunofluorescence
- LDH:
-
Lactic dehydrogenase
- MAHA:
-
Microangiopathic hemolytic anemia
- PE:
-
Plasma exchange
- SCr:
-
Serum creatinine
- TLC:
-
Total leucocyte count
- VWF:
-
Von Willebrand factor
References
Noris M, Remuzzi G (2010) Genetics and genetic testing in hemolytic uremic syndrome/thrombotic thrombocytopenic purpura. Semin Nephrol 30:395–408
Noris M, Remuzzi G (2009) Atypical hemolytic uremic syndrome. N Engl J Med 361:1676–1687
Constantinescu AR, Bitzan M, Weiss LS et al (2004) Non-enteropathic hemolytic uremic syndrome: causes and short-term course. Am J Kidney Dis 43:976–982
Stuhlinger W, Kourilsky O, Kanfer A, Sraer DJ (1974) Letter: haemolytic uremic syndrome: evidence for intravascular C3 activation. Lancet 2:788–789
Gonzalo A, Mampaso F, Gallego N et al (1981) Hemolytic uremic syndrome with hypocomplementemia and deposits of IgM and C3 in the involved renal tissue. Clin Nephrol 16:193–199
Roberts AW, Gillet EA, Fleming SJ (1991) Hemolytic uremic syndrome/thrombotic thrombocytopenic purpura: outcome with plasma exchange. J Clin Apher 6:150–154
Fitzpatrick MM, Dillon MJ, Barratt TM, Trompeter RS (1992) Atypical hemolytic uremic syndrome. In: Kaplan BS, Trompeter RS, Moake JL (eds) Hemolytic uremic syndrome and thrombotic thrombocytopenic purpura. Marcel Dekker, New York, pp 163–178
Laszik Z, Silva F (1998) Hemolytic-uremic syndrome, thrombotic thrombocytopenia purpura, and systemic sclerosis (systemic scleroderma). In: Jennett JC, Olson JL, Schwartz MM, Silva FG (eds) Heptinstall’s pathology of the kidney, 5th edn. Lippincott-Raven, Philadelphia, pp 1003–1057
Gasser C, Gautieer E, Steck A et al (1955) Hämolytisch-urämische syndrome: bilaterale Nierenrindennekrosen bei akuten erworbenen hämolytischen Anämien. Schweiz Med Wochenschr 85(905–909):929
Furlan M, Robles R, Galbususera M et al (1998) Von-Willebrand factor-cleaving protease in thrombotic thrombocytopenic purpura and haemolytic–uraemic syndrome. N Engl J Med 339:1578–1584
Tsai HM, Lian EC (1998) Antibodies to von Willebrand factor-cleaving protease in acute thrombotic thrombocytopenic purpura. N Engl J Med 339:1585–1594
Moake JL, Rudy CK, Troll KH et al (1982) Unusually large plasma factor VIII: von Willebrand factor multimers in chronic relapsing thrombotic thrombocytopenic purpura. N Engl J Med 307:1432–1435
Levy GG, Nichols WC, Lian EC et al (2001) Mutations in a member of the ADAMTS gene family cause thrombotic thrombocytopenic purpura. Nature 413:488–494
Lammle B (2002) The role of ADAMTS13 in the evaluation and management of patients with thrombotic thrombocytopenic purpura. In: Broudy VC, Abkowitz JL, Vose JM (eds) Hematology 2002: American society of hematology education program book. American Society of Hematology, Washington, pp 319–325
Hwang WYK, Chai LYA, Ng HJ, Goh YT, Tan PHC (2004) Therapeutic plasmapheresis for the treatment of the thrombotic thrombocytopenic purpura-haemolytic uraemic syndromes. Singap Med J 45:219–223
Hans von Baeyer (2002) Plasmapheresis in thrombotic microangiopathy-associated syndromes: review of outcome data derived from clinical trials and open studies. Ther Apher 6:320–328
Gianviti A, Perna A, Caringella A et al (1993) Plasma exchange in children with hemolytic-uremic syndrome at risk of poor outcome. Am J Kid Dis 22:264–266
Bandarenko N, Brecher ME (1998) United States thrombotic thrombocytopenic purpura apheresis study group (US TTP ASG): multicenter survey and retrospective analysis of current efficacy of therapeutic plasma exchange. J Clin Apher 13:133–141
George NJ, Gilcher RO, Smith JW et al (1998) Thrombotic thrombocytopenic purpura-hemolytic uremic syndrome: diagnosis and management. J Clin Apher 13:120–125
Dervenoulas J, Tsirigotis P, Bollas G et al (2000) Thrombotic thrombocytopenic purpura/hemolytic uremic syndrome (TTP/HUS): treatment outcome, relapses and prognostic factors. A single-center experience of 48 cases. Ann Hematol 79:66–72
Sarode R, Gottschall JL, Aster RH, McFarland JG (1997) Thrombotic thrombocytopenic purpura: early and late responders. Am J Hematol 54:102–107
Byrnes JJ, Moake JL, Klug P, Periman P (1990) Effectivness of the cryosupernatant plasma fraction in the treatment of refractory thrombotic thrombocytopenic purpura. Am J Hematol 34:169–174
Obrador GT, Zeigler ZR, Shadduck RK et al (1993) Effectiveness of cryosupernatant therapy in refractory thrombotic thrombocytopenic purpura. Am J Hematol 42:217–230
Rock G, Shumak KH, Sutton DMC, Buskard NA (1996) Nair RC and the members of the Canadian Apheresis Group. Cryosupernatant as replacement fluid for PEX in thrombotic thrombocytopenic purpura. Brit J Haematol 94:383–386
Bell WR, Braine HG, Ness PM, Kickler TS (1991) Improved survival in thrombotic thrombocytopenic purpura/hemolytic uremic syndrome: clinical experience in 108 patients. N Engl J Med 325:398–403
Elkins SL, Wilson PP Jr, Files JC, Morrison FS (1996) Thrombotic thrombocytopenic purpura: evolution across 15 years. J Clin Apher 11:173–175
Ramanan AS, Thirumala S, Chandrasekaran V (1999) Thrombotic thrombocytopenic purpura: a single institution experience. J Clin Apher 14:9–13
Lara PN, Coe TL, Zhou H et al (1999) Improved survival with plasma exchange in patients with thrombotic thrombocytopenic purpura-hemolytic uremic syndrome. Am J Med 107:573–579
Henon PH (1991) Traitement du purpura thrombotique thrombopénique: résultats d‘une étude cliniques multicentric randomisée. Presse Médical 20:1761–1767
Rock GA, Shumak KH, Buskard NA, Blanchette VS, Kelton JG, Nair RC, Spasoff RA (1991) Canadian Apheresis Study Group. Comparison of plasma exchange with plasma infusion in the treatment of thrombotic thrombocytopenic purpura. N Engl J Med 325:393–397
Amorosi EL, Ultmann JE (1966) Thrombotic thrombocytopenic purpura: report of 16 cases and a review of the literature. Medicine 45:139–159
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Patel, R.D., Vanikar, A.V., Gumber, M.R. et al. Diagnosis and Management of Atypical Hemolytic Uremic Syndrome In Children: Single Centre Experience. Indian J Hematol Blood Transfus 30, 342–346 (2014). https://doi.org/10.1007/s12288-013-0262-3
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s12288-013-0262-3